

PERSONAL INFORMATION Giulio Pompilio

CURRENT POSITION

Scientific Director, Monzino Cardiology Center IRCCS
Ordinary Professor of Cardiac Surgery, University of Milan
Private IRCCS representative at the Health Technical Committee-Section C, Ministry of Health of Health

From 12/6/2023 to present

Ordinary Professor of Cardiac Surgery

University of Milan, 7 Festa del Perdono Street, 20122, Milan, Italy
 Field of activity Department of Biomedical Surgical Sciences and Odontoiatrics

From 1/7/2020 to present

Scientific Director

Monzino Cardiology Center IRCCS, 4 Parea Street, 20138, Milan, Italy
 Field of activity Scientific Direction

From 1/3/2015 to 11/6/2023

Associate Professor of Cardiac Surgery (MED23)

University of Milan, 7 Festa del Perdono Street, 20122, Milan, Italy
 Field of activity Department of Biomedical Surgical Sciences and Odontoiatrics

PROFESSIONAL EXPERIENCE

From 1/5/2014 to 31/12/2023

Head of Vascular Biology and Regenerative Medicine Unit

Monzino Cardiology Center IRCCS, 4 Parea Street, 20138, Milan, Italy
 Field of activity Scientific Direction

From 1/3/2019 to 28/2/2020

Visiting Professor

INSERM Toulouse (FR)
 Field of activity Toulouse Institute of Cardiovascular and Metabolic Diseases

From 1/6/2005 to 30/6/2020

Senior Cardiac Surgeon

Monzino Cardiology Center IRCCS, 4 Parea Street, 20138, Milan, Italy
 Field of activity Cardiovascular Surgery Area, Cardiac Surgery Unit 1

From 7/10/2016 to 30/6/2020

Scientific Deputy Director

Centro Cardiologico Monzino IRCCS, via Parea 4, 20138, Milan, Italy
 Activity or sector Scientific Direction

From 9/2/2011 to 30/10/2016

Scientific Director

Italian Foundation for Research on Amyotrophic Lateral Sclerosis (AriSLA), via Poerio 14, 20129, Milan, Italy
 Activity or sector Scientific Direction

From 1/3/2006 to 28/2/2015

Senior Researcher

University of Milan, via Festa del Perdono 7, 20122, Milan, Italy
 Activity or sector Department of Clinical and Community Sciences

From 1/9/2008 to 30/4/2014

Clinical Manager

Centro Cardiologico Monzino IRCCS, via Parea 4, 20138, Milan, Italy
 Activity or sector Vascular Biology and Regenerative Medicine Laboratory

From 1/3/2004 to 31/5/2005

Head of the Biotechnologies Operational Unit in Cardiac Surgery

Monza General Hospital IAS, via Carlo Amati, 111, 20900, Monza, Italy

Activity or sector: Cardiac Surgery Operational Unit

From 1/1/1996 to 29/02/2004

Assistant/Senior Assistant of Cardiac Surgery

Monzino Cardiology Center IRCCS, via Parea 4, 20138, Milan, Italy

Activity or sector: Department of Cardiovascular Surgery

EDUCATION AND TRAINING

Health Management Course

2023

Bocconi University School of Management SDA, Via Roberto Sarfatti 25, 20136 Milan

2001

PhD in Cardiovascular Surgical Physiopathology

University of Milan, via Festa del Perdono 7, 20122, Milan, Italy

2000

Course in Experimental Microsurgery

University of Milan, via Festa del Perdono 7, 20122, Milan

From 1994 to 1995

Fellowship in Cardiac Surgery and Vascular Surgery

UCLouvain University Clinics of Mont-Godinne, Belgium

From 1989 to 1994

Specialization in Cardiac Surgery (70/70 summa cum laude)

University of Milan, via Festa del Perdono 7, 20122, Milan

From 1983 to 1989 Degree in Medicine and Surgery (110/110 summa cum laude)

University of Milan, via Festa del Perdono 7, 20122, Milan

From 1978 to 1983

Classical Maturity (60/60)

Classical High School "F. Delpino", Chiavari, Genoa.

PERSONAL SKILLS

Native language Italian

Other languages

	UNDERSTANDING		SPOKEN		WRITTEN PRODUCTION
	Listening	Reading	Interaction	Speaking	
English	C1	C1	C1	C1	C2
	Replace with the name of the language certificate obtained. Enter the level, if known				
French	C1	C2	C2	C2	A1
	Replace with the name of the language certificate obtained. Enter the level, if known				

Levels: A1/A2: Basic user - B1/B2: Intermediate user - C1/C2: Advanced user

[Common European Framework of Reference for Languages](#)

Organizational skills and

administrative

▪Executive manager in the Life Science sector with >25 years of experience in cardiovascular research, clinical innovation, technology transfer, and advanced therapies (ATMP). Proven track record in managing, multi-million clinical and experimental research programs at national and international levels, in implementing life science research ecosystems, and in the clinical introduction of innovative regenerative therapies. Proven leadership in managing research organizations, public-private partnerships, consortia of

research and technology transfer, and experience in biotech entrepreneurship.

- **For over 6 years, as Scientific Director, he is responsible for a team of about 120 people within the Scientific Directorate of the Centro Cardiologico Monzino IRCCS, with an overall budget of >€12M. Responsibility for strategic coordination and execution of the Institute's experimental and clinical scientific research. During the two three-year terms 2020-2026, Monzino's research revenues rose from €7,235,666 recorded in the 2020 financial statements to €13,790,000 in 2025, a CAGR of 14%.**
- **Representative of Private IRCCS at the Technical-Health Committee-Section C, Ministry of Health; August 2022-present.**
- **National Coordinator of the PerfeTTO Network, a PNC project under the PNRR Mission 6 of the Ministry of Health (Budget €30M). PerfeTTO is the first national network of Technology Transfer Offices (TTO) comprised of public and private Life Science research bodies (IRCCS, Universities and Research Centers) with 54 members in a ATS and 18 affiliates (2023-present).**
- **From 2018 to 2021 he held the role of Italian Alternate Member at the Committee for Advanced Therapies (CAT) of the European Medicines Agency (EMA).**
- **From 2011 to 2016 he served as Scientific Director of the Italian Foundation for ALS Research (ArisLA), with executive responsibility for personnel, fundraising, and portfolio project management.**
- **Responsible and Coordinator of Targeted and Strategic Research projects of the Ministry of Health, competitive research projects of the MUR, private national entities and foreign public and private entities (see the 'Projects' section).**
- **Responsible and Coordinator of Phase I-III clinical trials (see the 'Projects' section).**

Professional skills

Clinical and care activities:

- **Prof. Giulio Pompilio has as a primary operator a total cardio-surgical activity of over 1600 procedures. He has focused on beating-heart and minimally invasive coronary surgery, repair surgery of the ascending aorta and the mitral valve. He has performed more than 120 left internal mammary artery to the anterior left thoracotomy (LIMA-IVA) myocardial revascularization procedures (MIDCAB).**
- **Certified MitraClip transcatheter mitral repair system operator.**
- **From 2005 to 2020, Dr. Pompilio provided consulting services as a cardiovascular surgeon at the European Institute of Oncology (IEO-IRCCS, Milan), performing cardiac and vascular repair procedures within thoracic oncologic surgery, urological, gynecological, cervico-facial, and melanoma-sarcoma areas.**

Clinical and experimental research activities:

- **For over 25 years, Dr. Pompilio has been a clinical and translational researcher in cardiovascular regenerative medicine. He is a pioneer in Italy in the use of gene therapy for peripheral arterial disease and cellular and regenerative therapy for extensive myocardial infarction and refractory ischemic cardiomyopathy. He has served as PI and co-PI on numerous Phase I-III randomized clinical trials. He also has extensive experience as Manager of the Experimental Research Unit (Vascular Biology and Regenerative Medicine Research Unit - 2014-2025) focused on advanced cellular models and murine models of genetic and acquired cardiovascular disease.**
- **He has won research funding as Coordinator (PI) or Partner in national and international public and private competitive calls totaling €3,783,666. Dr. Pompilio has also received research contributions from reputable private institutions and patient associations totaling €795,123.**

Technology transfer activities:

Co-inventor of the following PIs:

- **Italian patent no. 102017000062176, international (PCT/IB2018/054057), and extended nationally in Europe, United States, Canada, Israel, Japan, China, Hong Kong, Australia, India, Singapore, Korea to the field bio-cell therapies: 'Method for isolating subpopulations of cardiac progenitor cells and related medical uses', licensed on 30/12/2020 for €911,000 to the cardiovascular cell therapy biotech start-up Oloker Therapeutics S.r.l. (www.oloher.com), of which Dr. Pompilio is co-founder and Advisor Board Chairman. Oloker has to date been funded by a private investor for R&D development totaling €6M.**
- **Italian patent application no. 102025000000006 titled 'Combination of active ingredients for use in restoring and/or maintaining the physiological function of the vascular endothelium and/or valve apparatus of the cardiovascular system', licensed on 29/07/2025 to Gricar S.r.l. and the Centro Cardiologico Monzino IRCCS.**

Academic activities:

- **Member of the Faculty Board of the PhD course in Translational and Molecular Medicine DIMET at the University of Milan-Bicocca (2007-present).**
- **Member of the Faculty Board of the PhD in Pharmacological Biomolecular, Experimental and Clinical Sciences at the University of Milan (2024-present).**
- **Lecturer in the course “Experimental Models of Cardiovascular Research”, Degree Course for Technicians in Cardiac Physiopathology and Cardiovascular Perfusion, University of Milan (2016-present).**
- **Lecturer in the course “Ventricular Assist Devices”, Degree Course for Technicians in Cardiac Physiopathology and Cardiovascular Perfusion, University of Milan (2019-present).**
- **Visiting Professor, INSERM Toulouse, France (2019-2020).**
- Course “Applied English in Cardiac Surgery”, School of Specialization in Cardiac Surgery, University of Milan (2017-2021).
- Course “Surgical Anatomy and Operative Technique in Cardiac Surgery”, School of Specialization in Cardiac Surgery, University of Milan (2016-2019).
- “Clinic of Surgical Diseases and Large Vessels”, School of Specialization in Cardiac Surgery, University of Milan (academic years 2006-2012).
- “Cardiac Surgery for the First Aid Course”, Degree Course in Techniques of Cardiocirculatory Physiopathology, University of Milan (academic years 2006-2012).
- formal, interactive, and tutoring teaching activity for Medical and Surgery students, for residents in Cardiac Surgery and Vascular Surgery, and for students in the Degree Course in Cardiocirculatory Physiopathology Techniques.

Other skills

- **Italian Delegate in the European Partnership for Innovative Health Initiative (IHI JU), public-private consortium with a budget of €2.3B; Jan. 2022-present.**
- **Member of the Technical-Scientific Committee of the Regional Foundation for Biomedical Research of Lombardy (FRRB); April 2025-present.**
- **Associate Editor, International Journal of Cardiology; 2024-present.**
- Chairman Elect (2022-2024) of the Working Group Cardiovascular Regenerative and Reparative Medicine (CARE) of the European Society of Cardiology (ESC). Currently Past-Chairman.
- Scientific Committee President, Osservatorio Terapie Avanzate (OTA); May 2022-present
- Member of the Board of Directors of the Regional Foundation for Biomedical Research of Lombardy (2015-2016).
- Member of the Technical-Scientific Committee of the Regional Foundation for Biomedical Research of Lombardy (2012-2015).
- Member of the Board of Nerviano Medical Science (NMS) Group (2012-2014).
- Member of the advisory scientific board of:
 - International Scientific Committee, Direction de la Recherche et de l'Innovation (DRI), Toulouse University (2015),
 - CELLforCURE Scientific Committee, LFB Group (French State Public Company), Paris (2016),
 - CellProthera (French Cell Therapy Company), Clinical Board Meeting, Paris (2017).
- Vice President, Associazione Medicina&Persona, Via Melchiorre Gioia 171, Milan (2008-2016).
- Executive/Associate Editor of Journal of Medicine and the Person (Ed. Limes, Milan, Italy) (2003-2008).
- National Coordinator of the Working Group on Cardiac Cell Therapy of the Italian Federation of Cardiology (FIC); 2007-2010.
- Advisory activities for competitive calls of the following Agencies:
 - Sardegna Ricerche – Planning Department, Sardinia Region (2015)
 - Ministry of Education, Universities and Research – MIUR (2014-2015)
 - Padua and Rovigo Foundation (2015)
 - Fund of the Mayor of the City of Vienna (2018)
 - Honorary reviewer for the GENDER-NET Plus Joint Call (ERA NET Horizon 2020, 2018)
 - French National Research Agency (Call 2018)
 - Swiss National Science Foundation (2023)
 - Slovenian Research and Innovation Agency (2024)
 - European Research Council (2023-26)

Driver's license

B

ADDITIONAL INFORMATION

Publications

▪ **Author of 295 scientific works reviewed on PubMed. Citations: 10499, H-index 47 (Scopus Database, 10/09/2026)**

Author of the following chapters of the book:

1. Pompilio G, Gennari M, Gambini E, Bassetti B, and Capogrossi MC. Refractory angina pectoris in the era of stem cell therapy. *Atherosclerotic Cardiovascular Disease*. Edited by Ksenija Pešek, 2011.
2. Pesce M, Pompilio G, and Capogrossi MC. Endothelial progenitor cells from human cord blood: Magic bullets against ischemia? In Niranjana Bhattacharya and Phillip Stubblefield Eds. *Frontiers in Cord Blood Science*, Springer-Verlag, UK, 2011.
3. Pesce M, Gambini E, Pompilio G, and Capogrossi MC. Cardiac stem cells: tales, mysteries and promises in heart generation and regeneration. In Gustav Steinhoff Ed. *Regenerative Medicine, from protocol to patient*. Springer, UK, 2011.
4. Pompilio G, Alamanni F, Biglioli P. Minimally invasive cardiac surgery: quality of life issues. From: *Contemporary Cardiology: Minimally Invasive Cardiac Surgery*, Second Edition. Editors: DJ Goldstein and MC OZ. Humana Press Inc., Totowa, NJ; 2004:369-381.

Projects

- Responsible for the following Current Research Projects (RC) funded by the Ministry of Health:

- Current Research 1996: Cryopreservation: effects on endothelial vitality of vessels and immunological properties in autologous heart valves
- RC 1997: Development of cardioplegic arrest models in isolated rat heart subjected to global ischemia
- RC 1999: Cardioplegic solution enriched in myocardial injury from ischemia and reperfusion: experimental and clinical protocol
- RC 2000: Biological markers of aging of arterial vessels.
- RC 2001: a) Biological markers of aging of arterial vessels; b) Glucose metabolism and coronary surgery.
- RC 2002: a) Cellular Cardiomyoplasty; b) MIDCAB and quality of life; c) Glucose metabolism and coronary surgery.
- RC 2003: Cellular Cardiomyoplasty.
- RC 2006: a) Circulating endothelial progenitors (EPC) and cardio-surgical intervention: prospective study of the short- and medium-term impact of cardiac surgery and extracorporeal circulation on EPC function. Correlation with clinical outcome; b) Circulating endothelial progenitors and carotid stents: prospective study of possible correlation between EPC functional data and degree of restenosis at mid-term; c) Phase II prospective randomized clinical trial of stem cell therapy using autologous stem cells in patients candidates for coronary bypass with ischemic cardiomyopathy; d) Pilot clinical trial of cellular therapy with autologous stem cells in patients with chronic critical limb ischemia (CCLI).
- RC 2007: a) Circulating endothelial progenitors (EPC) and cardio-surgical intervention: prospective study of short- and mid-term impact of cardio-surgical intervention and extracorporeal circulation; b) Circulating endothelial progenitors and carotid stents: prospective study of possible correlation between EPC functional data and degree of restenosis mid-term; c) Phase II prospective randomized clinical trial of cell therapy with autologous stem cells in patients candidate for coronary bypass with ischemic cardiomyopathy; d) Pilot clinical trial of cell therapy with autologous stem cells in patients with chronic critical limb ischemia (CCLI).
- RC 2008: a) Phase II prospective randomized clinical trial of cellular therapy with autologous stem cells in patients candidates for coronary bypass with ischemic cardiomyopathy; b) Pilot clinical trial of cellular therapy with autologous stem cells in patients with chronic critical limb ischemia (CCLI); c) Analysis of circulating microRNAs.
- RC 2009: a) Phase II prospective randomized trial of cellular therapy with autologous stem cells in patients candidates for coronary bypass with ischemic cardiomyopathy; b) Pilot clinical trial of cellular therapy with autologous stem cells in patients with chronic critical limb ischemia (CCLI); c) Analysis of circulating microRNAs.
- RC 2010: a) Pilot clinical trial of cellular therapy and gene therapy in patients with

critical chronic ischemia of the lower limbs (CCLI); b) Clinical trial of cell therapy with autologous stem cells in patients with ischemic cardiomyopathy; c) Development of a murine model of doxorubicin-induced dilated cardiomyopathy.

- RC 2011: Compassionate therapy with intramyocardial inoculation of autologous bone marrow cells in patients with refractory myocardial ischemia.

- RC 2012-2014: a) Genetic, epigenetic, and cellular bases of arrhythmogenic right ventricular dysplasia (ARVD); b) Compassionate therapy with intramyocardial inoculation of autologous bone marrow cells in patients with refractory myocardial ischemia.

- RC 2016-2018: Randomized controlled trial to define, based on post-operative renal outcome, the superiority of cardiopulmonary bypass conducted based on continuously measured DO₂ and VO₂ values compared to standard conduct.

- RC 2018: a) Evaluation of the role of peptidyl-prolyl isomerases in thoracic aortic aneurysm; b) Development of a biorepository for tissues, cells, fluids, and related patient data and of an iPSC facility for disease-modeling and drug-screening.

- RC 2019-2021: a) Pathological basis and biomarkers of thoracic aortic aneurysms; b) cardiovascular regenerative medicine; c) advanced cell models of cardiomyopathies.

- Responsible for the following competitive grant research projects as Project Coordinator (PI) for a total of €3,200,990:

- Targeted Research CO-2024-12378524 - PKP2 mRNA replacement through inhalable nanoparticles to treat arrhythmogenic cardiomyopathy- PLARNAGENT. Funding awarded € 200,000.00

- RCR-2022-23682288 - Integrated strategies for the study of tissue and molecular determinants of vulnerable atherosclerotic plaque - (Note DGRIC procedure no. 1401 of 13/04/2022). Funding awarded €224,000.00.

- PSC Health 2021, Trajectory 4 - "Biotechnologies, Bioinformatics and Pharmaceutical Development" CAL.HUB.RIA (CALabria HUB for Innovative and Advanced Research). Funding awarded €873,000.00.

- RCR-2021-23671212 - Cat.B-PRV-RETE CARDIO - "Cardiovascular manifestations in long covid: diagnostic evidence, thrombotic, infectious, immunological, cellular and tissue inflammatory mechanisms" (CF CARDIO NETWORK - RCR 2021 Funds - Note no. 2548 of 22/06/2021). Funding awarded €321,580.00.

- Marfan Foundation Research Grant 2020 (F-MARFAN-21-POMPILIO): Study of EMMPRIN as a possible novel therapeutic target for thoracic aortic aneurysms in Marfan syndrome. Funding awarded \$100,000.00.

- Telethon Foundation Call 2018: Towards Precision Medicine with Human Induced Pluripotent Stem Cells for Dystrophin Associated Cardiomyopathy. Funding awarded € 128,750.00.

- ERA-CVD Joint Transnational Call 2016: Cardiomyocyte - non-myocyte interplay as a novel platform for mechanistic insights and therapeutic approaches in ACM heart failure. Funding awarded € 344,200.00.

- Telethon Foundation Call 2015: Contribution of lipids and their oxidized metabolites on Arrhythmogenic Cardiomyopathy pathogenesis. Funding awarded € 193,050.00.

- Capital Account 2015 (Ministry of Health): Development of a platform of human cardiomyocytes derived from induced pluripotent stem cells (iPSCs) for the study of cardiomyopathies with genetic etiology through a "high-throughput" approach. Funding awarded € 164,090.00.

- Veronesi Foundation Call 2013: In vitro and in vivo investigation of miR-34a as a potential therapeutic target in vascular calcification. Funding awarded € 115,000.00.

- Independent Research 2013 Lombardy Region: Randomized placebo-controlled study of mobilization of bone marrow progenitors with G-CSF in patients with ventricular dysfunction following extensive anterior myocardial infarction: STEM-AMI2 trial. Funding awarded € 300,000.00.

- Targeted Research 2010 (Ministry of Health): Phase I/II trial of NOGA-guided endocavitary injection of bone-marrow-derived CD133+ cells in ischemic refractory cardiomyopathy (RECARDIO trial). Funding awarded € 237,320.00.

- Responsible for the following competitive research projects as Coordinator of the Operational Unit (Unit Partner-UO) for a total of €582,676:

- FISR2020 COVID: Patient-specific mini-hearts to stratify the risk of myocarditis following SARS-CoV-2 infection (SASSOON). €28,259.00
- PRIN 2015 (MIUR): Arrhythmogenic cardiomyopathy: cross-talk among cardiomyocytes, stromal cells and sympathetic neurons in disease pathogenesis. € 62,500.00
- Independent Research 2009 (Region of Lombardy): Micro-RNAs as new early markers of myocardial ischemia. € 105,000.00
- PRIN 2008 (MIUR): Use of stem cells for a therapeutic approach in cardiology. € 38,640.00
- Stem Cells 2008 (Ministry of Health): MicroRNA bioengineering of human cardiac mesenchymal cells and heart regeneration. € 87,000.00
- Targeted Research 2007 (Ministry of Health): Identification of proteomic/ proinflammatory and immune biomarkers in patients with Acute Coronary Syndromes at high risk to develop clinical events: genomic and proteomic approaches. € 93,375.00
- Targeted Research 2002 (Ministry of Health): Therapeutic angiogenesis for the formation of capillaries and arterioles with selective angiogenic factors. € 64,000.00
- Strategic Research 2000 (Ministry of Health): Vascular injury and dysmetabolisms: genetic-molecular characterization, prevention and intervention. € 142,542.10

- Responsible for the following projects from research contracts & donations from patient associations for a total of €795,123:

- Oloker Therapeutics (2020): CPCPlus Technology development plan. €384,048.80
- Italfarmaco S.p.a (2017). Screening of a putative therapeutic drug Givinostat in cardiomyocytes derived from Duchenne and Becker muscular dystrophy patient-specific induced pluripotent stem cells. €23,215.00
- Associazione Amici Alfisti Biuke (2017). Role of PPIase in thoracic aortic aneurysm. €2,500.00
- Flamma S.p.a (2017). Evaluation of treatment with L-Carnosinol in a murine model of critical limb ischemia. € 13,660.00
- Single patient donation (2016). Characterization and treatment of factors influencing the severity of arrhythmogenic cardiomyopathy. € 39,600.00
- PALL Italia Srl (2013). In vitro potency characterization of the Celeris™ WB System for Total Nucleate Cell enrichment. € 67,100.00
- Fondazione Monzino 2008: Creation of the Experimental Surgical Laboratory for cardiovascular regenerative therapy. € 265,000.00

- Participated as PI and Co-PI in the following phase I-III clinical trials of cardiovascular regenerative therapy:

- Phase I clinical study of endocavitary intramyocardial injection of CD133+ cells derived from bone marrow for the treatment of refractory ischemic cardiomyopathy (RECARDIO trial); 2013-present.
- National Phase III trial mobilization of bone marrow progenitors with G-CSF in patients with ventricular dysfunction following extensive anterior myocardial infarction (STEM-AMI OUTCOME); 2013-2018.
- Prospective, double-blind, randomized, placebo-controlled clinical trial of intracoronary infusion of mesenchymal precursors (mesenchymal cell precursors, MPC) Stro3 immunoselected derived from bone marrow, in the treatment of patients with ST-elevation myocardial infarction (AMICI); 2015-2016.
- Phase II clinical study, randomized, double-blind, placebo-controlled, parallel-group, on the efficacy and safety of NV1FGF in patients with intermittent claudication: long-term safety (TALISMAN-SURVEY LTS11315); 2010-2011.
- Randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of 4 administrations of XRP0038/NV1FGF at 4 mg every 2 weeks on amputation or death from any cause in patients with critical limb ischemia and skin lesions (TAMARIS); 2008-2010.
- Autologous bone marrow stem cell transplant for myocardial regeneration within a coronary bypass operation: randomized controlled clinical trial; 2007-2010.

- Phase II clinical trial, randomized, double-blind, placebo-controlled, parallel-group, evaluating the efficacy and safety of NV1FGF in patients with intermittent claudication (TALISMAN-PM211); 2002-2004.

Awards and recognitions

- Chairperson of the ESC Working Group on Cardiovascular Regenerative and Reparative Medicine (2022-2024).

- Best Poster in stem cells, ESC Congress 2017: Endocavitary injection of bone-marrow-derived CD133+ cells in ischemic Refractory Cardiomyopathy,
- The RECARDIO Enterprise project selected among the top 5 BIOINIZIATIVA Scouting Program projects for the Techno Scouting event by Finlombarda (Lombardy Region).

Membership in groups / associations

- Fellow of the European Society of Cardiology (FESC).
- Member of the international research group for regenerative medicine in cardiovascular syndromes: Transatlantic Alliance for regenerative Therapies In Cardiovascular Syndromes (TACTICS Group) 2015-present.

Fellowships/Advanced courses

- Training of the Intramyocardial Injection Helix Infusion System, Hospital General Universitario Gregorio Marañón, Madrid, Spain, June 2013.
- Training-Proficiency Test of the Intramyocardial Injection Catheter C-Cath, Medanex Clinic, Diest, Belgium, October 2012.
- NOGA-XP training for cell delivery in porcine myocardium, at Stem Cell Center, Texas Heart Institute, USA (Dr. E. Perin), October-November 2008.
- Master of Valve Repair – Advanced Course, at Leiden University Medical Center, Netherlands (Coordinator: Prof. R. Dion), 14-16 March 2005.
- Training on Surgical Treatment of Atrial Fibrillation, at Centro Cardiologico Monzino IRCCS, July 17, 2002.
- Post-Graduate Course: “Aortic and mitral surgery. Focus on echocardiographic and technical aspects.” May 31 – June 1, 2002, Brussels, Belgium (Director: Prof. G El Khoury)
- Training course “Management control systems”, at ERISMAS, Milan, 5-7 November 2001.
- International Course: “From Genetic to Gene Therapy”, International Atherosclerosis Society, Lugano 8-10/2/2001 (Directors: Prof. Humphries SE, Prof. Vassalli G)
- Post Graduate Course “Thoracic and Thoraco-Abdominal Aortic Aneurysms Live Surgery”, Bologna, 20-21 November 1998 (Director: Prof. A. Pierangeli).

Personal data

I authorize the processing of my personal data pursuant to Legislative Decree 30 June 2003, no. 196 (Personal Data Protection Code) and its subsequent amendments and integrations, as well as Regulation EU 679/2016 (General Data Protection Regulation or, more briefly, GDPR).

Milan 10/09/2026

GIULIO POMPILIO MD PhD